Oncology Clinical Trials in Syracuse, NY

As of July 2026, 45 paid clinical trials are recruiting for Oncology in Syracuse, New York. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

45 clinical trials for Oncology

·Clear filters·↓ Download CSV

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

Sites in Syracuse, Rochester +143 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

for Venous Thromboembolism

1 location in Syracuse

Sponsor: Kiranya Arnold

Sex: All·Age: 18 - 89

Code: NCT07189897·Phase 4·Recruiting·Listed Sep 2025

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

Sites in Syracuse, Rochester +54 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting·Listed Feb 2013

Apply to this trial

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

for Prostate Cancer

Drug: Saruparib

Sites in Syracuse, New York +36 more locations

Sponsor: AstraZeneca

Sex: Male·Age: 18+

Code: NCT06952803·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

Sites in Syracuse, New York +42 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial